[Use of rHu GM-CSF (Leucomax) in treatment of neutropenia during intensive chemotherapy for acute lymphoblastic leukemia]

Acta Haematol Pol. 1994;25(2):111-8.
[Article in Polish]

Abstract

15 children with ALL and chemotherapy related neutropenia were treated with GM-CSF (Leucomax-Sandoz/Schering-Plough) in a dose of 5 micrograms/kg b.w./day during 7-10 days. Altogether 21 cycles were performed. Increase in the number of neutrophils in the majority of cases was observed already after 3 days of GM-CSF administration. The median time of neutropenia recovery was shorter in children treated with GM-CSF than in the control group. The frequency of severe infections was also significantly lower. No serous side effects were observed.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Male
  • Neutropenia / drug therapy*
  • Neutropenia / etiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome

Substances

  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor